Weight-Loss Drugs Like Wegovy Don't Cause Suicidal Thoughts, EU Says
By Dominic Chopping
The European Union's drug regulator found no link between the class of medicines behind Novo Nordisk's blockbuster Ozempic and Wegovy treatments and reports of suicidal thoughts in patients.
A study by a European Medicines Agency committee had been looking at potential links between the popular weight-loss and diabetes drugs and reports of suicidal and self-harming thoughts from people using them, but it said Friday that the evidence doesn't support a causal association.
The U.S. Food and Drug Administration came to the same conclusion in January while British health authorities are carrying out their own review.
Novo Nordisk's Ozempic and Wegovy share the same active ingredient, semaglutide, which belongs to a class of drug known as GLP-1 and works by mimicking a hormone to produce more insulin, lower blood glucose and slow stomach emptying after eating, helping to treat both type 2 diabetes and obesity.
The regulator's committee studied both treatments as well as several other medications that use GLP-1s, including diabetes drugs such as AstraZeneca's Byetta, Sanofi's Lyxumia and Eli Lilly's Trulicity.
The probe started in July last year following reports of suicidal thoughts from patients using the medicines and the committee requested additional data from the pharmaceutical companies on the medications in November.
The committee analyzed the results of a large study based on health records that tracked the incidence of suicidal thoughts in obesity and type 2 diabetes patients using either semaglutide or non-GLP-1 drugs. It also conducted its own study based on health records to examine the risks of suicide or self harm in type 2 diabetes patients using GLP-1 drugs.
The study didn't include Eli Lilly's Mounjaro and Zepbound diabetes and weight-loss drugs, which work slightly differently to traditional GLP-1 medications.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
April 12, 2024 10:09 ET (14:09 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
How to Invest Like Warren Buffett
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025